P
Paul W. Noble
Researcher at Cedars-Sinai Medical Center
Publications - 244
Citations - 40869
Paul W. Noble is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Pulmonary fibrosis. The author has an hindex of 81, co-authored 226 publications receiving 35910 citations. Previous affiliations of Paul W. Noble include San Francisco VA Medical Center & Duke University.
Papers
More filters
Journal ArticleDOI
American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias
William D. Travis,Talmadge E. King,Eric D. Bateman,David A. Lynch,Frédrique Capron,Thomas V. Colby,Jean-François Cordier,Roland M. Dubois,Jeffrey R. Galvin,Philippe Grenier,David M. Hansell,Gary W. Hunninghake,Masanori Kitaichi,Nestor L. Müller,Jeffrey L. Myers,Sonoko Nagai,Andrew G. Nicholson,Ganesh Raghu,Benoit Wallaert,Christian Brambilla,Kevin K. Brown,Andrew L. Cherniaev,Ulrich Costabel,David B. Coultas,Gerald S. Davis,Maurits G. Demedts,William W. Douglas,Jim J. Egan,Anders Eklund,Leonarda M. Fabbri,Craig A. Henke,Richard Hubbard,Y. Inoue,Takateru Izumi,H. M. Jansen,Ian Johnston,Dong Soon Kim,Nasreen Khalil,Fiona R. Lake,Giuseppe Lungarella,Joseph P. Lynch,Douglas W. Mapel,Fernando J. Martinez,Richard A. Matthay,Lee S. Newman,Paul W. Noble,Ken Ohta,Dario Olivieri,Luis A. Ortiz,Venerino Poletti,Robert Rodriguez-Roisin,William N. Rom,Jay Hoon Ryu,Paulo Hilário Nascimento Saldiva,Raúl H Sansores,Marvin L. Schwarz,Moisés Selman,Cecelia M. Smith,Zhaohui Tong,Zarir F Udwadia,Dominique Valeyre,Athol U. Wells,Robert A. Wise,Antonio Xaubet,Emilio Alvarez Fernandez,Elisabeth Brambilla,Vera Luiza Capelozzi,Andrew Cherniaev,Peter Dalquen,Gerhard Dekan,Philip S. Hasleton,James C. Hogg,N. A. Jambhekar,Anna Luise A Katzenstein,Michael Koss,Osamu Matsubara,Klaus Michael Müller,F. B.J.M. Thunnissen,James A. Waldron,Wei Hua Li,Paul J. Friedman,Martin Remy-Jardin,Theresa C. McLoud +82 more
TL;DR: The Diagnostic Process Is Dynamic Clinical Evaluation Radiological Evaluation Role of Surgical Lung Biopsy Unclassifiable Interstitial Pneumonia Bronchoalveolar Lavage Fluid Evaluation Idiopathic Pulmonary Fibrosis.
Journal ArticleDOI
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more
TL;DR: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintinganib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W. Noble,Carlo Albera,Williamson Z. Bradford,Ulrich Costabel,Marilyn K. Glassberg,David Kardatzke,Talmadge E. King,Lisa Lancaster,Steven A. Sahn,Javier Szwarcberg,Dominique Valeyre,Roland M. du Bois +11 more
TL;DR: In this article, the CAPACITY program was designed to confirm the results of a phase 2 study that suggested that pirfenidone, a novel antifibrotic and anti-inflammatory drug, reduces deterioration in lung function in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation
TL;DR: Assessment of risk by a combination of maternal age and fetal nuchal-translucency thickness, measured by ultrasonography at 10-14 weeks of gestation, finds that selection of the high-risk group for invasive testing by this method allows the detection of about 80% of affected pregnancies.